Health and Fitness Health and Fitness
Fri, April 1, 2011
[ Fri, Apr 01st 2011 ] - Market Wire
Form 8.3 - Chaucer Holdings Plc
[ Fri, Apr 01st 2011 ] - Market Wire
Candax Reports 2010 Results
[ Fri, Apr 01st 2011 ] - Market Wire
30 p.m. ET
Thu, March 31, 2011

AKELA PHARMA REPORTS RESULTS THE THREE MONTHS AND YEAR ENDED 2010


Published on 2011-03-31 21:00:22 - Market Wire
  Print publication without navigation


AUSTIN, TX, March 31 /CNW/ - Akela Pharma, Inc. ("Akela") (TSX: AKL), a leader in the development of therapeutics for the treatment of pain, and the company's wholly owned subsidiary, PharmaForm, today announced its financial results for the three months and year ended December 31, 2010.

Total consolidated revenues for the three months ended December 31, 2010 were $3.7 million, including $3.0 million of contract services, as compared to $3.0 million, including $2.4 million of contract services, for the same period during the previous year. For the year ended December 31, 2010, total consolidated revenues were $13.3 million, including $10.2 million of contract services, as compared to $13.9 million, including $10.6 million of contract services, for 2009.

Consolidated net income for the three and twelve months ended December 31, 2010 were $1.5 million, $0.05 per share, and $1.2 million, $0.04 per share, versus losses of $14.1 million, ($0.46) per share, and losses of $21.0 million, ($.77) per share, for the same respective periods in 2009.

Excluding one time gains and losses, Akela's consolidated net income for the three and twelve months ended December 31, 2010 were $0.8 million, and $0.5 million, versus a net loss of $2.2 million, and a net loss of $8.4 million.

             
             
          Three months ended     Year ended
          December 31,     December 31,
              2010         2009              2010     2009
                         
Income (loss) before under noted items     771     (2,199)      524     (8,445)
Other (expenses) income:                        
  Settlement with LRI      -     -     -      1,664
  Impairment of goodwill, intangible and other assets                           -              (9,601)                          -              (9,601)
  Lease termination      -     (1,936)     -      (1,936)
  Provision for repayment of government grants      -     -     -     (1,544)
  Restructuring      -     (263)     -     (1,071)
Income (loss) before income taxes     771     (13,999)     524     (20,933)
(Provision for) recovery of income taxes:                        
  Current     707     (64)     707     (64)
  Future       -     -      -                     -
        707     (64)     707                   (64)
                            
Net income (loss) and comprehensive income (loss)   $              1,478   $      (14,063)    $              1,231   $      (20,997)
                            
Basic and diluted net income (loss) per share   $ 0.05   $ (0.46)   $ 0.04   $ (0.77)
                           
Basic and diluted weighted average number of shares      32,207,005     30,890,338     31,563,255     27,283,487

 

The Company had a cash balance of $0.5 million as of December 31, 2010 compared with $0.1 million as of December 31, 2009.

About Akela Pharma Inc.

Akela Pharma is a drug development company with its lead product, Fentanyl TAIFUN®, being developed for the treatment of breakthrough cancer pain. Fentanyl TAIFUN is a fast-acting fentanyl formulation delivered using the company's TAIFUN multi-dose dry powder inhaler platform.

About PharmaForm

PharmaForm, Akela's wholly owned subsidiary, is a leading specialty contract service provider in the area of pharmaceutical dosage form development and manufacturing, specializing in controlled release and bioavailability enhancement technologies, such as hot melt extrusion, liquid filled capsules, and spray drying. Through its diverse offerings, PharmaForm solutions help pharmaceutical and biotechnology clients reach their development targets, reduce development costs and accelerate time-to-market.

Akela's common shares trade on The Toronto Stock Exchange ("TSX") under the symbol "AKL" with 32.4 million shares outstanding.

This press release contains statements which may constitute forward-looking information under applicable Canadian securities legislation or forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1955. Such forward-looking statements or information may include financial and other projections as well as statements regarding the company's future plans, objectives, performance, revenues, growth, profits, operating expenses or the company's underlying assumptions. The words "may", "would", "could", "will", "likely", "expect", "anticipate", "intend", "plan", "forecast", "project", "estimate" and "believe" or other similar words and phrases may identify forward-looking statements or information. Persons reading this press release are cautioned that such statements or information are only expectations, and that the company's actual future results or performance may be materially different.

Forward-looking statements or information in this press release include, but are not limited to, statements or information concerning our ongoing drug development programs and collaborations as well as the possible receipt of future payments upon achievement of milestones.

Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments to be materially different from results, events or developments expressed or implied by such forward-looking statements or information. Such factors include, among others, the possibility that risks associated with requirements for approvals by government agencies such as the FDA before products can be tested in clinical trials; the possibility that such government agency approvals will not be obtained in a timely manner or at all or will be conditioned in a manner that would impair our ability to advance development; risks associated with the requirement that a drug candidate be found safe and effective after extensive clinical trials; our dependence on suppliers, collaborative partners and other third parties and the prospects and timing for negotiating supply agreements, corporate collaborations or licensing arrangements; our ability to attract and retain key personnel; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at [ http://www.sedar.com ].

Assumptions underlying our expectations regarding forward-looking statements or information contained in this press release include, among others, that future clinical trial results will be favorable; that our drug candidate will treat target diseases as intended; that we will raise enough capital, on reasonable terms and in a timely manner; that we will retain our key personnel; that we will obtain the necessary regulatory approvals.

In the event that any of these assumptions prove to be incorrect, or in the event that we are impacted by any of the risks identified above, we may not be able to continue in our business as planned.

For a complete discussion of the assumptions, risks and uncertainties related to our business, you are encouraged to review our filings with Canadian securities regulatory authorities, filed on SEDAR at [ http://www.sedar.com ].

All forward-looking statements and information made herein are based on our current expectations as of the date hereof and we disclaim any intention or obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.



AKELA PHARMA INC.
Consolidated Balance Sheets

As at December 31st
(in thousands of US dollars, except share and per share data)

            2010         2009
                       
Assets                        
                     
Current assets:                       
                   
  Cash          $   474     $   107
  Restricted cash             -         938
  Accounts receivable            1,590         1,679
  Prepaid expenses and other current assets           302         417
                         2,366         3,141
                   
Property and equipment         3,085          4,165
Intangible assets                  74            52
Other assets             67          598
                           
            $   5,592     $   7,956
                     
Liabilities and Shareholders' Deficiency                   
                     
Current liabilities:                       
                   
  Accounts payable and accrued liabilities   $   5,709     $   7,801
                     
  Deferred revenue            3,527             2,795
  Income taxes payable           266          
  Current portion of long-term debt           1,037         1,015
          10,539         11,611
                     
Deferred revenue         12,979          14,630
Income taxes payable                            799
Long-term debt       6,443         6,615
                   
            $   29,961     $   33,655
Shareholders' deficiency:                     
  Common shares (unlimited authorized,  32,390,338 and 30,890,338
common shares issued and outstanding with no par value at
December 31, 2010 and December 31, 2009, respectively) 
      67,739         67,544
  Warrants                 2,287         2,954
  Additional paid-in capital           9,082         8,511
                        
  Accumulated other comprehensive income           3,110         3,110
  Deficit                 (106,587)         (107,818)
  Total shareholders' deficiency       (24,369)           (25,699)
                         
Commitments, contingencies and guarantees                   
                                
     $   5,592     $   7,956

See accompanying notes to audited consolidated financial statements.



AKELA PHARMA INC.
Consolidated Statements of Operations and Comprehensive Loss

As at December 31st
(in thousands of US dollars, except share and per share data)

                   
          2010         2009
Revenues   $            13,302     $            13,893
                     
Expenses:                  
  Direct Costs                  5,446                    8,158
  Selling, general and administrative                  4,953                    6,183
  Research and development                     118                    3,711
  Stock-based compensation                       64                       238
  Amortization of property and equipment                  1,437                    1,464
  Amortization of intangible assets                       58                    1,693
  Interest on long-term debt                  1,090                       268
  Unrealized and realized loss on securities held for trading                       78                         23
  Foreign exchange gain (loss)                   (466)                       600
                     
                     12,778                  22,338
  Income (loss) before under noted items                     524                  (8,445)
                     
Other (expenses) income:                  
                     
  Settlement with LRI                        -                    1,664
  Impairment of goodwill, intangible and other assets                        -                  (9,601)
  Lease termination                        -                  (1,936)
  Provisions for repayment of government grants                        -                  (1,544)
  Restructuring                        -                  (1,071)
Income (loss) before income taxes                     524                (20,933)
(Provision for) recovery of income taxes                     
  Current                     707                       (64)
  Future                        -                          -
                        707                       (64)
                   
Net income (loss) and comprehensive income (loss)   $              1,231     $          (20,997)
Basic and diluted net income (loss) per share   $                0.04     $              (0.77)
Basic and diluted weighted average number of shares outstanding         31,535,338           27,283,487

See accompanying notes to the audited consolidated financial statements.



AKELA PHARMA INC.     
Consolidated Statements of Cash Flows

Years ended December 31, 2010 and 2009
(in thousands of US dollars, except share and per share data unless otherwise noted)

        Year
ended
        December 31,
                       
        2010       2009
                       
Cash flow from operating activities:                    
  Net Income (loss) and comprehensive income (loss)   $   1,231     $   (20,997)
  Adjustments for:                    
    Amortization of property and equipment       1,437         1,412
    Amortization of intangible assets       58         1,745
    Impairment of intangible and other assets         -         9,601
    Loss on disposal of equipment under capital lease                                         76         -
    Lease Termination       -         1,936
    Provision for repayment of government grants         -         1,544
    Restructuring         -         471
    Settlement with LRI       -         (101)
    Stock-based compensation         64         238
    Unrealized foreign exchange loss       (466)         649
    Realized and unrealized loss on securities held for trading         78         23
    Income Taxes         -         64
    Capitalized interest       887                   -
                       
  Net changes in working capital       (3,498)         1,653
          (133)         (1,762)
                       
Cash flows from financing activities:                    
                   
    Repayment of long-term debt       (410)         (1,517)
            (410)         (1,517)
                       
Cash flows from investing activities:                    
    Acquisition of property and equipment       (28)         (1,036)
    Cash acquired of Nventa         -         1,157
    Restricted Cash         938         920
          910         1,041
                       
Net increase (decrease) in cash       367         (2,238)
Cash, beginning of year       107         2,345
                       
Cash, end of year     $   474     $   107